Siiquent and Teomik aren’t just different brands; they operate in different economies. Isolde’s Siiquent sells into hospitals and diagnostic labs—buyers constrained by budgets, compliance, and uptime. That’s why a razor-and-blades approach fits: instruments near cost, profits from reagents and test kits, with experiments like pay-per-test to ease purchasing friction. Emanuel’s Teomik serves research labs and universities, where status, grants, and capability matter more than reimbursement rules. There, customers pay premium prices for cutting-edge instruments and treat consumables as secondary. Each revenue model grew out of its market’s logic.
The merger question: pick one model or keep flexibility; tempts easy answers. A single model can simplify operations, unify messaging, and create scale efficiencies. But it also risks amputating product–market fit, because hospitals and research labs don’t buy for the same reasons. Flexibility preserves responsiveness and innovation, right up until it creates cross-subsidies, channel conflict, and moral hazard. Siiquent’s pay-per-test, for example, solved friction but also invited overuse and waste. The real move isn’t to crown a winner; it’s to set guardrails so each model serves its market without tripping the other.
If I’m the PM asked to mediate a forced merge, I would scaffold the process rather than the answer. First, I would make reality shared: one page per unit that captures target customer, job-to-be-done, unit economics (hardware and consumables margins, CAC/LTV), compliance constraints, and top failure modes. No adjectives—just numbers—so we align on facts before preferences. Next, I would help the leaders agree on principles that will outlive today’s debate: customer trust over short-term tricks, safety and compliance as non-negotiables, and pricing that follows delivered value with clear total cost of ownership. With principles in place, I’d map overlaps to standardize (service SLAs, uptime guarantees) and isolate true differences (procurement cycles, funding sources) into parallel tracks with explicit interfaces for pricing rules, discount authority, and transfer pricing on shared components.
To learn, I’d run bounded experiments in adjacent segments like teaching hospitals with research arms. One variant could mirror Teomik’s premium hardware with capped-price reagents; another could mirror Siiquent’s low-cost hardware with outcome-indexed reagents. We would pre-register success metrics—gross margin dollars, reorder rate, downtime, NPS—and set red lines to prevent misuse. Borrowing from HBR’s “How to Speak Up When It Matters,” I’d reduce social threat (“we’re testing models, not egos”) and use if-then voice plans: if a metric crosses a red line, then the PM must flag it and the group pauses the trial. Each test would have a single accountable owner, a biweekly review, and a hard kill-or-scale decision at 90 days to avoid zombie models.
The golden point: don’t merge by choosing a revenue model; merge by choosing principles and guardrails, then let data pick where models converge—and let real differences remain where they should.
